BioMarin (BMRN) CAO receives 25,610 RSUs and 18,220 stock options

Rhea-AI Filing Summary

BioMarin Pharmaceutical’s VP and Chief Accounting Officer, Rashmi Virendra Ramchandani, reported new equity awards. On January 20, 2026, she received 18,540 shares of common stock and a separate grant of 7,070 shares, both at a stated price of $0, which the footnotes describe as restricted stock units granted on that date. After these awards, she directly beneficially owned 25,610 common shares.

She was also granted a stock option covering 18,220 shares of common stock at an exercise price of $56.31 per share. The option becomes exercisable as to 12/48 of the grant on January 20, 2027, with the remaining 1/48 vesting on the 20th day of each month thereafter, and it expires on January 19, 2036. These transactions reflect equity compensation rather than open‑market buying or selling.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramchandani Rashmi Virendra

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL

770 LINDARO STREEET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		18,540	A	$0(1)	18,540	D
Common Stock	01/20/2026		A		7,070	A	$0(1)	25,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$56.31	01/20/2026		A		18,220		01/20/2027(2)	01/19/2036	Common Stock	18,220	$0	18,220	D

Explanation of Responses:

1. Restricted stock units granted on January 20, 2026. Price not applicable.

2. Option grant vests 12/48th on January 20, 2027 and 1/48th on the 20th day of each month thereafter.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did BioMarin (BMRN) grant to its VP, Chief Accounting Officer?

On January 20, 2026, BioMarin granted VP and Chief Accounting Officer Rashmi Virendra Ramchandani restricted stock units covering 18,540 shares and a separate grant of 7,070 shares of common stock, both recorded at a price of $0 as equity compensation.

How many BioMarin (BMRN) common shares does the reporting person own after these grants?

Following the reported equity grants on January 20, 2026, the reporting person directly beneficially owned 25,610 shares of BioMarin common stock.

What stock option was granted to the BioMarin (BMRN) executive and at what exercise price?

The executive received a stock option for 18,220 shares of BioMarin common stock with an exercise price of $56.31 per share, as reported in the derivative securities table.

What is the vesting schedule for the newly granted BioMarin (BMRN) stock option?

According to the footnote, the option grant vests 12/48th on January 20, 2027, and 1/48th on the 20th day of each month thereafter, until fully vested, with an expiration date of January 19, 2036.

Were these BioMarin (BMRN) Form 4 transactions open-market purchases or sales?

No. The Form 4 shows acquisitions coded "A" at a price of $0, and the footnotes describe them as restricted stock units and a stock option grant, indicating they are equity compensation awards, not market trades.

What role does the reporting person hold at BioMarin (BMRN)?

The reporting person, Rashmi Virendra Ramchandani, is an officer of BioMarin, serving as VP, Chief Accounting Officer, as indicated in the filing.